Influence of tumour size on uptake of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model

被引:57
作者
Harrington, KJ
Rowlinson-Busza, G
Syrigos, KN
Abra, RM
Uster, PS
Peters, AM
Stewart, JSW
机构
[1] Hammersmith Hosp, Imperial Coll Sci Technol & Med, Imperial Canc Res Fund, Oncol Unit, London W12 0HS, England
[2] Mayo Clin, Program Mol Med, Rochester, MN 55902 USA
[3] SEQUUS Pharmaceut Inc, Menlo Park, CA USA
[4] Hammersmith Hosp, Imperial Coll Sci Technol & Med, Dept Imaging, London W12 0HS, England
[5] Charing Cross Hosp, Dept Radiotherapy, London W6, England
关键词
pegylated liposome; tumour targeting; vascularity; xenograft;
D O I
10.1054/bjoc.2000.1320
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between tumour size and uptake of In-111-DTPA-labelled pegylated liposomes has been examined in a human head and neck cancer xenograft model in nude mice. The mean tumour uptake of In-111-labelled pegylated liposomes at 24 hours was 72 +/- 6.6% ID/g. Liposome uptake for tumours < 0.1 g, 0.1-1.0 g and > 1.0 g was 15.1 +/- 10.8, 5.9 +/- 2.2 and 3.0 +/- 1.3% ID/g, respectively. An inverse correlation between tumour weight and liposome uptake was observed by both Spearman's rank correlation test (r(s) = -0.573, P < 0.001) and Pearson's correlation coefficient (r(s) = -0.555, P < 0.001). For 18 tumours with macroscopic central necrosis, the ratio of uptake in the tumour rim relative to the necrotic tumour core was 11.2 +/- 6.4. Measurement of tumour vascular volume for tumours of various sizes revealed an inverse correlation between tumour weight and tumour vascular volume (Spearman's rank correlation test, r(s) = -0.598, P < 0.001), consistent with poor or heterogeneous vascularization of larger tumours, These data have important implications for the clinical application of pegylated liposome targeted strategies for solid cancers which are discussed in detail. (C) 2000 Cancer Research Campaign.
引用
收藏
页码:684 / 688
页数:5
相关论文
共 22 条
[1]   DIFFUSION OF UNIVALENT IONS ACROSS LAMELLAE OF SWOLLEN PHOSPHOLIPIDS [J].
BANGHAM, AD ;
STANDISH, MM ;
WATKINS, JC .
JOURNAL OF MOLECULAR BIOLOGY, 1965, 13 (01) :238-+
[2]  
BEANEY RP, 1984, LANCET, V1, P131
[3]  
BOGNER JR, 1994, J ACQ IMMUN DEF SYND, V7, P463
[4]  
EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362
[5]  
GABIZON A, 1994, CANCER RES, V54, P987
[6]  
GABIZON A, 1990, CANCER RES, V50, P6371
[7]   LIPOSOME FORMULATIONS WITH PROLONGED CIRCULATION TIME IN BLOOD AND ENHANCED UPTAKE BY TUMORS [J].
GABIZON, A ;
PAPAHADJOPOULOS, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (18) :6949-6953
[8]  
GABIZON AA, 1994, HEMATOL ONCOL CLIN N, V8, P431
[9]   Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma [J].
Goebel, FD ;
Goldstein, D ;
Goos, M ;
Jablonowski, H ;
Stewart, JS .
BRITISH JOURNAL OF CANCER, 1996, 73 (08) :989-994
[10]   DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY [J].
GREGORIADIS, G ;
WILLS, EJ ;
SWAIN, CP ;
TAVILL, AS .
LANCET, 1974, 1 (7870) :1313-1316